Maochen Li

Maochen Li

Auto-generated profile, based on publicly available information

Maochen Li

College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2022 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
MLMaochen Li
Maochen Li
HWHan Wang
Han Wang
LTLili Tian
Lili Tian
ZPZehan Pang
Zehan Pang
QYQingkun Yang
Qingkun Yang
HFHuahao Fan
Huahao Fan
With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern (VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 vaccines mainly include inactivated, live attenuated, viral vector, protein subunit, RNA, DNA, and virus-like particle (VLP) vaccines. Viral vector vaccines, protein subunit vaccines, and mRNA vaccines may induce additional cellular or humoral immune regulations, including Th cell responses and germinal center responses, and form relevant memory cells, greatly improving their efficiency. However, some viral vector or mRNA vaccines may be associated with complications like thrombocytopenia and myocarditis, raising concerns about the safety of these COVID-19 vaccines. Here, we systemically assess the safety and efficacy of COVID-19 vaccines, including the possible complications and different effects on pregnant women, the elderly, people with immune diseases and acquired immunodeficiency syndrome (AIDS), transplant recipients, and cancer patients. Based on the current analysis, governments and relevant agencies are recommended to continue to advance the vaccine immunization process. Simultaneously, special attention should be paid to the health status of the vaccines, timely treatment of complications, vaccine development, and ensuring the lives and health of patients. In addition, available measures such as mix-and-match vaccination, developing new vaccines like nanoparticle vaccines, and optimizing immune adjuvant to improve vaccine safety and efficacy could be considered.

20 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
LLLiang Leng
Liang Leng
ZXZhichao Xu
Zhichao Xu
BHBixia Hong
Bixia Hong
BZBinbin Zhao
Binbin Zhao
YTYa Tian
Ya Tian
SCShilin Chen
Shilin Chen
Cepharanthine is a secondary metabolite isolated from Stephania. It has been reported that it has anti-conronaviruses activities including severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Here, we assemble three Stephania genomes (S. japonica, S. yunnanensis, and S. cepharantha), propose the cepharanthine biosynthetic pathway, and assess the antiviral potential of compounds involved in the pathway. Among the three genomes, S. japonica has a near telomere-to-telomere assembly with one remaining gap, and S. cepharantha and S. yunnanensis have chromosome-level assemblies. Following by biosynthetic gene mining and metabolomics analysis, we identify seven cepharanthine analogs that have broad-spectrum anti-coronavirus activities, including SARS-CoV-2, Guangxi pangolin-CoV (GX_P2V), swine acute diarrhoea syndrome coronavirus (SADS-CoV), and porcine epidemic diarrhea virus (PEDV). We also show that two other genera, Nelumbo and Thalictrum, can produce cepharanthine analogs, and thus have the potential for antiviral compound discovery. Results generated from this study could accelerate broad-spectrum anti-coronavirus drug discovery.

27 September 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
MLMaochen Li
Maochen Li
FLFuxing Lou
Fuxing Lou
HFHuahao Fan
Huahao Fan

28 January 2022 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
MLMaochen Li
Maochen Li
FLFuxing Lou
Fuxing Lou
HFHuahao Fan
Huahao Fan

16 September 2022 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
YCYangzhen Chen
Yangzhen Chen
MLMaochen Li
Maochen Li
HFHuahao Fan
Huahao Fan

10 April 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
MLMaochen Li
Maochen Li
FLFuxing Lou
Fuxing Lou
HFHuahao Fan
Huahao Fan
The spike protein of SARS-CoV-2 is the target of antibodies in convalescent and vaccine sera, and 23 mutations in spike protein were reported in the variants B.1.1.7, B.1.351, and P.1 (Fig. 1a). Recently, several groups evaluated the effects of convalescent and mRNA vaccine sera on two major circulating SARS-CoV-2 variants B.1.1.7 and B.1.351 (Fig. 1b), 1-5 which leads to concerns about the immune escape of these variants from the human acquired immunity stimulated by previous infections and mRNA vaccines. By 27 March 2021, COVID-19 has caused more than 126.1 million infections and 2,768,409 deaths (https://coronavirus.jhu. edu/), and some countries have already developed vaccines against SARS-CoV-2. Different from the inactivated vaccines approved in China, the western countries are prone to develop mRNA vaccines or viral vector vaccines (e.g., Oxford-AstraZeneca vaccine ChAdOx1 nCoV-19 (AZD1222) and Pfizer-BioNTech vaccine BNT162b2), targeting the spike protein, whose mutations deserve consistent monitoring. Because of the instability of SARS-CoV-2 RNA and error-prone replication, viral mutations appear frequently. 1,2 Until now, 114, 67, and 36 countries have reported the discovery of variants B.1.1.7, B.1.351, and P.1, respectively (covlineages.org/global_report.html). Given these mutations may cause higher viral load and longer infection duration in the infected persons, 3 the effects of B.1.1.7 and B.1.351 variants on virus infection and vaccine efficiency were studied by several groups, respectively (Fig. 1b). 1,2,4,5 Supasa, P. et al. analyzed 180,000 sequences from the COG-UK database (https://www.cogconsortium.uk) and found that B.1.1.7 strain with amino acid 69 and 70 of spike protein deletion (Δ69/70) occupied the dominant position among the three subgroups (the other subgroups lack this deletion), which indicated selective advantages existed in the variation process of SARS-CoV-2. 1 And N501Y mutation existing in all B.1.1.7, B.1.351, and P.1 variants were found to enhance the affinity between receptor-binding domain (RBD) and angiotensin-converting enzyme 2 (ACE2) by about 7-fold compared with wild type (WT). According to the data released by Public Health England, the infectivity of B.1.1.7 variant is 30-50% higher than that of the wild type (WT), which may result from the increased affinity between RBD and ACE2. 3 Then the neutralization activities of 20 potent monoclonal antibodies for WT were detected by focus reduction neutralization tests, and a remarkable neutralization activity reduction was found in IGHV3-53 mAbs (e.g., mAb269 almost completely lost neutralization activity and mAb278 only retained 78% activity at most). In addition, the authors tested the efficacy of neutralizing antibodies in vaccine sera. The vaccine